By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Johannes Kepler University of Linz: Injection against heart attacks

David Bernhard © JKU

Taking action quickly can help to save lives. Researchers at the Johannes Kepler University of Linz are now developing an injection with which emergency physicians can save about 20 percent of the patient’s heart muscle from dying off. The new drug has already been successfully tested in the laboratory.

In the case of a heart attack, part of the heart is cut off from the oxygen supply. The surrounding heart tissue is not fully supplied with ultimately first ties after some time. This issue can be saved thanks to the new development of Prof. David Bernhard, Head of the Center for Medical Research at Johannes Kepler University of Linz. He developed a substance named 5`-Methoxyleoligin. The special property of this substance is that it not only protects the insufficiently supplied heart issue from the effects of the heart attack but can also be administered intravenously. Up until now treatment of the heart could first take place in a hospital within the context of a surgical procedure. Methoxyleoligin is originally derived from the roots of the edelweiss but can be synthetically produced in the meantime. All in all, experts from six Austrian universities worked on the project for several years under the leadership of the University of Linz.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Life Sciences Wien - Ein Markt mit vielen Chancen

    28.01.2021, 10:00 - 11:30 (CET), Online Conference

  • Meet us @ HTH Styria!

    28.1.2021, 10:00 - 16:15 (CET) , Online Conference

Austria Map

Find the perfect location for your company

Vienna’s unique location at the heart of Europe makes it an important centre and very popular with the global pharmaceutical and biotechnology industry. Vienna is where Eastern Europe meets Western Europe. Businesses located at this international hub benefit from well-established infrastructures and highly-qualified professionals. The significant growth in the Life Sciences sector in Vienna over the last few years is an indicator of the momentum in the industry.

ABF Pharmaceutical Services

ABF Pharmaceutical Services
More testimonials

news from the business location Austria

Austrian government creates investment premium for investors

The economic and financial consequences of the COVID-19 crisis pose major challenges to companies. In order to strengthen the Austrian business location, the Austrian Federal Government has resolved upon a new investment promotion program for companies with a total volume of EUR 3 billion, which will be further increased, if necessary.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts